JGC
ZVRA icon

J. Goldman & Co’s Zevra Therapeutics ZVRA Stock Holding History

J. Goldman & Co’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-97,500
Closed -$813K – 674
2024
Q4 		$813K Buy
97,500
+94,100
+2,768% +$803K 0.02% 342
2024
Q3 		$23.6K Buy
+3,400
New +$23.1K ﹤0.01% 437

Other funds holding ZVRA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

J. Goldman & Co's ZVRA Position: Q1 2026 in Review

J. Goldman & Co held its Zevra Therapeutics (ZVRA) position steady in Q1 2026 at 13,497 shares worth $126K. The position accounts for ﹤0.01% of the portfolio, ranked #613.

J. Goldman & Co first reported a position in ZVRA in Q4 2018 and has held it in 8 quarters since. The position peaked at $7.3M in Q4 2024. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

  • J. Goldman & Co held 13,497 shares of Zevra Therapeutics worth $126K as of Q1 2026.
  • J. Goldman & Co left its Zevra Therapeutics share count unchanged in Q1 2026.
  • Zevra Therapeutics made up ﹤0.01% of J. Goldman & Co's portfolio in Q1 2026, its #613 holding.
  • J. Goldman & Co first reported a position in Zevra Therapeutics in Q4 2018 and has held it in 8 quarters since.
  • J. Goldman & Co's Zevra Therapeutics position peaked at $7.3M in Q4 2024.
  • 148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.